AXQ Capital LP Acquires New Holdings in DexCom, Inc. $DXCM

AXQ Capital LP bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 12,977 shares of the medical device company’s stock, valued at approximately $873,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its holdings in shares of DexCom by 2.5% during the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock worth $474,000 after purchasing an additional 169 shares during the period. Inspire Investing LLC raised its position in DexCom by 6.1% during the 3rd quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock worth $211,000 after purchasing an additional 180 shares during the last quarter. Personal CFO Solutions LLC lifted its holdings in DexCom by 5.0% during the 3rd quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock worth $260,000 after buying an additional 185 shares during the period. Inspire Advisors LLC lifted its holdings in DexCom by 2.5% during the 3rd quarter. Inspire Advisors LLC now owns 7,926 shares of the medical device company’s stock worth $533,000 after buying an additional 194 shares during the period. Finally, Integrated Wealth Concepts LLC grew its position in shares of DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after buying an additional 196 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on DXCM. Morgan Stanley restated an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. TD Cowen dropped their price target on DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a research note on Friday, October 31st. BTIG Research restated a “buy” rating and issued a $85.00 target price on shares of DexCom in a research note on Friday, February 13th. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 16th. Finally, Barclays reiterated an “underweight” rating and issued a $72.00 target price (up previously from $71.00) on shares of DexCom in a report on Friday, February 13th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus target price of $85.18.

DexCom Stock Performance

DexCom stock opened at $73.26 on Tuesday. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $91.87. The firm has a market capitalization of $28.19 billion, a PE ratio of 34.89, a price-to-earnings-growth ratio of 1.42 and a beta of 1.49. The firm’s 50 day simple moving average is $69.64 and its 200 day simple moving average is $69.24.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. The business had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The company’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.45 EPS. As a group, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.